Law Office of Brodsky & Smith, LLC Announces Investigation of Genoptix, Inc.
24 Enero 2011 - 10:00PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Genoptix, Inc. (“Genoptix” or the “Company”) (Nasdaq: GXDX)
relating to the proposed acquisition by Novartis AG (NYSE: NVS) in
a transaction valued at approximately $470 million.
Under the terms of the offer, Genoptix shareholders would
receive cash of $25.00 for each share of Genoptix stock they own.
The investigation concerns possible breaches of fiduciary duty and
other violations of state law. The transaction appears to be
unfair, in part, given the 52 week high trading high for the
Company’s stock was $38.79 a share. Additionally, at least one
analyst has set a target price of $28.00 for Genoptix stock.
If you own shares of Genoptix and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, or by calling toll free
877-LEGAL-90.
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about Genoptix, Inc. (MM) (NASDAQ): 0 recent articles
Más de Brodsky & Smith, LLC Artículos de Noticias